TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17041001
Drug: Risedronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 2.5 mg/day (group R)
Study: 17041001
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of risedronate and alfacalcidol (group R+A)
Study: 17051709
Drug: Local hyperthermia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local hyperthermia using balloon-type electrodes in combination with standard chemo- and radiotherapy
Study: 11555746
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation combined with cognitive behavioral therapy
Study: 31985112
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg nightly for five nights
Study: 23583817
Drug: PVRV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV administered intramuscularly (1 ml)
Study: 23583817
Drug: PVRV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV administered intradermally (0.1 ml)
Study: 23583817
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available PVRV (Verorab) administered intramuscularly
Study: 21958773
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy targeting LDL levels less than 100 mg/dL
Study: 21958773
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy targeting LDL levels less than 70 mg/dL
Study: 21958773
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with LDL levels >100 mg/dL
Study: 16385088
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at 150 to 200 mg per day
Study: 14666440
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg x kg(‐1) (group midazolam)
Study: 10971792
Drug: orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: orlistat 120 mg three times daily
Study: 8782006
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholic acid (10 mg kg‐1)
Study: 8782006
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg kg‐1)
Study: 1616093
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate spray (30 s before induction)
Study: 1616093
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate spray (90 s before induction)
Study: 1616093
Drug: Placebo buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo buccal spray (90 s before induction)
Study: 27430256
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg BID for 12 months
Study: 17135183
Drug: Ceftriaxone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone administered by 24 h continuous infusion
Study: 17135183
Drug: Ceftriaxone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone administered by once‐daily intermittent bolus dosing
Study: 16266472
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg per day)
Study: 7889440
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at doses of 80 to 1300 mg (Part 1)
Study: 7889440
Drug: Chronic dose
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic dose of ASA (325 mg) (Part 2)
Study: 2228924
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment during double-blind trials
Study: 657455
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium (100 mEq) with 200ml of 5% dextrose in water intravenously
Study: 657455
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium (100 mEq) with placebo capsules orally
Study: 657455
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium (50 mEq) in patients with primary adrenocortical insufficiency
Study: 657455
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium (50 mEq) in patients with primary adrenocortical insufficiency
Study: 26037286
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) in addition to antiplatelet therapy
Study: 26037286
Drug: PAR-1 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PAR-1 antagonists in addition to antiplatelet therapy
Study: 23515265
Drug: Daily median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily median estimated pulmonary artery diastolic pressures (ePAD)
Study: 21757376
Drug: GIN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIN therapy (high-dose insulin at 5 mU/kg/min during surgery)
Study: 21757376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (insulin on a sliding scale aiming at normoglycemia)
Study: 19539104
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of alendronate sodium 70 mg
Study: 19539104
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of alendronate sodium 70 mg
Study: 9989882
Drug: Peripheral blood
Normalized name: Peripheral blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood stem cell (PBSC) collection with mobilising chemotherapy (cyclophosphamide, etoposide, doxorubicin, cytosine arabinoside) and G-CSF, total of 47 courses.
Study: 9989882
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous stem cell rescue (21 of 37 patients).
Study: 2741191
Drug: Clindamycin 900
Normalized name: clindamycin 900 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 900 mg every 8 h admixed with gentamicin 1.5 mg/kg every 8 h (8-h group)
Study: 2741191
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg every 6 h given separately (6-h group)
Study: 31567873
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d PhytoSERM for 12 weeks
Study: 31567873
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d PhytoSERM
Study: 30636738
Drug: Idalopirdine 60
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idalopirdine 60 mg/day as adjunctive therapy
Study: 30636738
Drug: Idalopirdine 60
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idalopirdine 60 mg/day as adjunctive therapy with memantine
Study: 30636738
Drug: Idalopirdine 60
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idalopirdine 60 mg/day
Study: 30636738
Drug: Idalopirdine 60
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idalopirdine 60 mg/day with memantine
Study: 21255982
Drug: Haloperidol, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, mean dosage 4.14 mg (±1.70), duration 42.92 days (±16.85)
Study: 21255982
Drug: Risperidone, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone, mean dosage 4.17 mg (±1.55), duration 42.92 days (±16.85)
Study: 11180021
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of mycophenolate mofetil alone (study 1)
Study: 11180021
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of mycophenolate mofetil and 2 tablets of iron ion preparations (study 2)
Study: 3100007
Drug: Diltiazem (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (all doses)
Study: 3100007
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg (challenge after treatment)
Study: 3100007
Drug: Diltiazem (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (sustained therapy)
Study: 27160475
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus goserelin (10.8 mg goserelin by subcutaneous injection on the first day of irradiation and 3 months later)
Study: 17990049
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg per day (one patient received just 5 mg)
Study: 1752498
Drug: Concentrated 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated 25% albumin infusion for the first 16 hours after surgery
Study: 1752498
Drug: Concentrated 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated 25% albumin infusion
Study: 1752498
Drug: Standard crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard crystalloid solution
Study: 7043498
Drug: Pimozide (40‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (40‐60 mg/day)
Study: 7043498
Drug: Haloperidol (40‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (40‐60 mg/day)
Study: 26845265
Drug: Lithium and
Normalized name: Lithium and/or lithium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium and Quetiapine (both with adjunctive personalized treatments)
Study: 17698900
Drug: vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin (100 mg) with glibenclamide (5 mg)
Study: 17698900
Drug: vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin (100 mg) without glibenclamide (5 mg)
Study: 17698900
Drug: glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide (5 mg)
Study: 12609779
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus transplantation of cultured melanocytes (CC)
Study: 12609779
Drug: Only cryotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only cryotherapeutic treatment (OC)
Study: 10588768
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) and praziquantel (40 mg/kg body weight)
Study: 8941458
Drug: Two-injection scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-injection scheme (regimen A)
Study: 8941458
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glibenclamide with one injection of NPH insulin at bedtime (regimen B)
Study: 8941458
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glibenclamide with one injection of NPH insulin before breakfast (regimen C)
Study: 8941458
Drug: Overall insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overall insulin treatment
Study: 8941458
Drug: Combined insulin-sulfonylurea
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined insulin-sulfonylurea treatment
Study: 1949134
Drug: Recombinant sporozoite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant sporozoite vaccine
Study: 31140114
Drug: Ticagrelor pediatric
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor pediatric tablets taken whole
Study: 31140114
Drug: Ticagrelor pediatric
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor pediatric tablets suspended in water
Study: 31140114
Drug: Ticagrelor pediatric
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor pediatric tablets and granules for oral suspension
Study: 23646469
Drug: Qingyang Toujie
Normalized name: BENZODODECINIUM BROMIDE 2 g in 500 mL EXTRACORPOREAL LIQUID [Youjie Weishi Antibacterial Hand Wash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingyang Toujie Mixture (QTM) in combination with prednisone tablet
Study: 23646469
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with prednisone tablet
Study: 19180891
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment with density 1 settings
Study: 19180891
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment with density 2 settings
Study: 19180891
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment with density 3 settings
Study: 17419458
Drug: Cardioversion management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioversion management principles; specific details on dosage and duration not available.
Study: 10960627
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate/10 microg ethinyl E2
Study: 10960627
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate/5 microg ethinyl E2
Study: 10960627
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg norethindrone acetate/1 microg ethinyl E2, 0.5 mg norethindrone acetate/2.5 microg ethinyl E2, 1 mg norethindrone acetate/5 microg ethinyl E2
Study: 1638587
Drug: Cefprozil 500
Normalized name: cefprozil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil 500 mg once daily (or 20 mg/kg once daily) for 5 to 10 days
Study: 1638587
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg three times daily (or 20 mg/kg daily in three equal doses) for 5 to 10 days
Study: 6143736
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg propranolol i.v.
Study: 6143736
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg mepindolol sulfate i.v.
Study: 30466891
Drug: Custirsen added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custirsen added to first-line chemotherapy with docetaxel
Study: 20426957
Drug: Guaifenesin compound
Normalized name: guaiFENesin compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaifenesin compound pseudoephedrine hydrochloride oral solution
Study: 20426957
Drug: Ambroxol hydrochloride
Normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol hydrochloride oral solution
Study: 10404707
Drug: Nonresponders during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders during pharmacotherapy
Study: 7551920
Drug: CDDP (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (120 mg/m2 day 1) + etoposide (100 mg/m2 days 1‐3) every 3 weeks (PE‐‐arm A)
Study: 7551920
Drug: CDDP (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (120 mg/m2 every 4 weeks) + mitomycin (8 mg/m2 days 1, 29, 71) + vindesine (3 mg/m2 days 1, 8, 15, 22 every 2 weeks) (MVP‐‐arm B)
Study: 7551920
Drug: CDDP (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (120 mg/m2 day 1) + mitomycin (6 mg/m2 day 1) + ifosfamide (3 g/m2 day 2) every 3 weeks (MIC‐‐arm C)
Study: 28732826
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler (GFF MDI) 2.4/9.6 mug
Study: 28732826
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 mug
Study: 20078201
Drug: Mandibular symphysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular symphysis bone grafting followed by postoperative orthodontic treatment
Study: 9819039
Drug: rFVIIa (NovoSeven)
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (NovoSeven) administered at home
Study: 7648636
Drug: China-mode Hepatitis
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: China-mode Hepatitis A attenuated live vaccine
Study: 339935
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg three times a day)
Study: 339935
Drug: Mianserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (10 mg three times a day)
Study: 30661847
Drug: Yoga-CaRe program
Normalized name: PEPPLUS SPECIAL SKIN CARE LIFTING PROGRAM KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-CaRe program (13 sessions supervised by an instructor and encouragement to self-practice daily)
Study: 25832425
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg, po)
Study: 21696982
Drug: NV1FGF (riferminogene
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV1FGF (riferminogene pecaplasmid) administered intramuscularly
Study: 19476405
Drug: Intranasal phototherapy
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phototherapy (allergy reliever SN‐206) used three times a day for 14 days
Study: 8453387
Drug: Medication discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication discharge planning program (experimental group)
Study: 3530897
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg nocte (once at night)
Study: 29794099
Drug: Coordination exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordination exercises with concurrent mental tasks
Study: 15821888
Drug: HAART (Highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (Highly Active Antiretroviral Therapy) for six months
Study: 7899367
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for small cell lung carcinoma
Study: 144378
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered amine fluorides
Study: 29508695
Drug: HMB-FA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-FA (3 g/d)
Study: 25052410
Drug: Doxylamine-vitamin B6
Normalized name: doxylamine / vitamin B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine-vitamin B6 combination (Diclectin)
Study: 23033348
Drug: Prethrombolytic antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prethrombolytic antihypertensive treatment (AHT)
Study: 23033348
Drug: No prethrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prethrombolytic antihypertensive treatment (AHT)
Study: 15965279
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron (200 mg daily)
Study: 8676931
Drug: Three-drug group
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug group (rifabutin 600 mg daily, ethambutol, clarithromycin 1000 mg twice daily)
Study: 8676931
Drug: Three-drug group
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug group (rifabutin 600 mg)
Study: 8676931
Drug: Four-drug group
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug group (rifampin, ethambutol, clofazimine, ciprofloxacin)
Study: 8676931
Drug: Three-drug group
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug group (rifabutin 300 mg)
Study: 6287835
Drug: No mineral
Normalized name: Multi-Vitamin No Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mineral supplements (Control)
Study: 28201821
Drug: Cane group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cane group (using a cane daily whenever walking for 12 weeks)
Study: 26273472
Drug: Group-based Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based Mindfulness-Based Cognitive Therapy (MBCT)
Study: 26273472
Drug: Individual internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual internet-based Mindfulness-Based Cognitive Therapy (MBCT)
Study: 20846363
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human follicle-stimulating hormone
Study: 9972772
Drug: PGE1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 at a dose of 0.02 microg x kg(‐1) x min(‐1) (PG20 group)
Study: 9972772
Drug: PGE1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 at a dose of 0.05 microg x kg(‐1) x min(‐1) (PG50 group)
Study: 8775774
Drug: Locally applied
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally applied vaginal conjugated estrogen cream
Study: 28106471
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% bromfenac sodium
Study: 24396024
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg for 8 weeks